Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
Neuroendocrine tumor (NET) occurring in association with other endocrine syndromes forms a distinct entity. The aim was to assess the therapy response profile of the routine peptide receptor radionuclide therapy (PRRT) in this relatively uncommon but clinically challenging subgroup of patients. A re...
Main Authors: | Chinna Naik, Sandip Basu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
Series: | World Journal of Nuclear Medicine |
Subjects: | |
Online Access: | http://www.wjnm.org/article.asp?issn=1450-1147;year=2017;volume=16;issue=2;spage=126;epage=132;aulast=Naik |
Similar Items
-
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-01-01) -
Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01) -
A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
by: Pashtoon Murtaza Kasi, et al.
Published: (2019-01-01) -
177Lu-DOTATATE peptide receptor radionuclide therapy in patients with borderline low and discordant renal parameters: Treatment feasibility assessment by sequential estimation of triple parameters and filtration fraction
by: Chinna Naik, et al.
Published: (2018-01-01) -
Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: Evaluation of response and hematological toxicity profile of PRRT with 177Lu-DOTATATE
by: Sandip Basu, et al.
Published: (2016-01-01)